Endocyte rallies as vintafolide PRECEDENT results published

|By:, SA News Editor

After tumbling some 20% late last week on news that the vintafolide monotherapy arm in TARGET was (in the opinion of the DSMB) not likely to be declared superior to docetaxel in terms of PFS, Endocyte (ECYT +10.9%) recoups some of its losses as Phase 2 data shows vintafolide plus PLD resulted in a median PFS of 5 months in women with platinum-resistant ovarian cancer versus 2.7 months for the PLD alone group.

The Hazard Ratio was 0.63.

The results were published in the Journal of Clinical Oncology. (PR)